$10.58 0.62 (+6.22%)
11/6/2009 4:00 PM

Momenta Pharmaceuticals, Inc. (MNTA)

CAPS Rating: 4 out of 5

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

Current Price $10.58 Mkt Cap $422.1M
Open $9.84 P/E Ratio 0.00
Prev. Close $9.96 Div. (Yield) N/A (N/A)
Daily Range $9.81 - $10.65 Volume 649,248
52-Wk Range $6.47 - $12.56 Avg. Daily Vol. 579,000

MNTA News and Commentary

Caps

How do you think MNTA will perform vs the S&P 500?

Add Stock to Watchlist

All Members

290 Outperform
20 Underperform
 

All-Star Members

111 Outperform
7 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top MNTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ETFinnovators (< 20)
Submitted January 04, 2009

Momenta Pharma: A Pure Play on Bio-Generics

Momenta Pharma (MNTA) represents a pure play investment for the future of bio-generics, with two ANDAs filed at the FDA in partnership with the Sandoz division of Novartis (NVS) for multi-billion… More

1 Comment | Reply | Report this Post

cashsage (60.05)
Submitted January 24, 2009

MNTA has a too high valuation compared to its sales potential. It is one of the most loss making companies.

0 Comments | Reply | Report this Post
MNTA VS S&P 500 (SPY)

Fools bullish on MNTA are also bullish on:

Fools bearish on MNTA are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about MNTA.

Recs

0
Member Avatar minifesto (< 20) Submitted: 10/27/2009 2:43:28 PM : Outperform Start Price: $9.86 MNTA Score: +6.98

Sugar spialist. Market value $400 million. Cash $120 million. Pipeline of Generic, novel and follow-on drugs. Two partnerships with Sandoz. Strategy duplicate and re-engineer existing drugs using sugar technology. Raised $46.7 million at $10.15 per share end September 2009. Sandoz purchased 4.7 million shares at $15.93 July 2006. The first Sandoz partnership for generic version of Lovenox was signed November 2003.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar InTheTrenches (46.93) Submitted: 8/31/2009 3:52:44 PM : Outperform Start Price: $9.88 MNTA Score: +1.74

FDA decision on generic Lovenox is expected soon, which I think will be positive for MNTA.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar latimerburned (80.82) Submitted: 8/15/2009 9:06:37 AM : Outperform Start Price: $9.59 MNTA Score: +1.43

This one is a bit of a gamble. It either runs out of money as its drugs are not approved and goes to zero or it shoots very much higher when one of them is approved. The way I see it is you have 100% downside but 200%+ on the upside so I am going with outperform on this one.

Report this Post 0 Comments | Reply | Permalink
View All 52 Pitches »

Leaderboard

Find the members with the highest scoring picks in MNTA.

Score Leader

Pressonj

Pressonj (< 20) Score: +193.96

The Score Leader is the member with the highest score across all their picks in MNTA.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
subodhgupta 73.50 11/9/2007 Outperform 5Y $5.04 +109.92% -23.50% +133.43
odmonk 48.25 11/26/2007 11/20/2008 Outperform 1Y $5.11 +107.05% -22.29% +129.33 1 Comment
coolebo 72.38 11/9/2007 Outperform 3Y $5.24 +101.91% -23.20% +125.10
ripcord114 76.15 12/3/2007 Outperform NS $5.30 +99.62% -23.88% +123.50
rcocoma < 20 11/9/2007 Outperform 3W $5.30 +99.81% -23.68% +123.49
tbolioli 96.93 11/8/2007 Outperform 5Y $5.36 +97.39% -24.16% +121.55
FrankCast1e 67.94 11/20/2007 Outperform 5Y $5.31 +99.25% -22.07% +121.32
baller89 68.91 11/28/2007 Outperform 5Y $5.32 +98.87% -22.16% +121.03
GilB4u 74.69 11/16/2007 Outperform 1Y $5.36 +97.39% -23.28% +120.67
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. ChiouMoney 70.91 12/3/2007 Outperform 5Y $5.43 +94.84% -24.26% +119.10
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackDeutscheSec 89.50 9/19/2009 Outperform NS $11.71 -9.65% -0.02% -9.63
TrackWedbush < 20 5/19/2009 Outperform NS $9.59 +10.32% +18.72% -8.39
TrackStanfordRes 80.42 2/13/2009 Outperform NS $12.03 -12.05% +30.31% -42.36
TrackLeerinkSwan 84.26 1/5/2009 Outperform NS $11.26 -6.04% +17.78% -23.82
TrackRodmanRen < 20 4/29/2008 Outperform NS $15.57 -32.05% -20.26% -11.79
TrackBearStearns 86.38 10/12/2007 Underperform NS $12.35 -14.33% -27.80% -13.47

Featured Broker Partners